Antihemophilic factor (recombinant), porcine sequence - Biologic Drug Details

Summary for antihemophilic factor (recombinant), porcine sequence

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), porcine sequence Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), porcine sequence Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), porcine sequence Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Antihemophilic Factor (Recombinant), Porcine Sequence

Introduction

Acquired hemophilia A (AHA) is a rare and severe bleeding disorder characterized by the presence of autoantibodies against factor VIII (FVIII), leading to a significant decrease in FVIII activity. The treatment of AHA has seen a significant advancement with the introduction of recombinant porcine FVIII (rpFVIII), marketed as Obizur by Baxter. Here, we delve into the market dynamics and financial trajectory of this biologic drug.

Market Overview of Hemophilia A Treatment

The global Hemophilia A treatment market is substantial and growing. As of 2023, the market size was valued at USD 9.86 billion and is anticipated to grow to USD 15.96 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period[4].

Approval and Clinical Significance of rpFVIII

rpFVIII was approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of bleeding episodes in patients with AHA. This approval marked a significant milestone as rpFVIII is the first recombinant porcine FVIII treatment that allows for the measurement of FVIII activity levels, enabling better monitoring of treatment efficacy and safety[5].

Clinical Advantages Over Bypassing Agents

Bypassing agents (BPAs) such as recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCCs) have been the traditional treatment options for AHA. However, BPAs have several disadvantages, including the inability to monitor response with standard laboratory assays, inconsistent hemostatic efficacy, and a risk of thrombosis. In contrast, rpFVIII offers the advantage of laboratory monitoring and known hemostatic efficacy, even in the presence of anti-human FVIII inhibitors and after the failure of BPAs[1][2].

Algorithm-Based Dosing and Efficacy

Clinical experience has shown that an algorithm-based approach to dosing rpFVIII can be highly effective. Studies have demonstrated successful hemostatic outcomes at doses lower than the FDA-recommended dosing, highlighting the potential for reduced costs and improved patient outcomes. This approach allows for rapid dose adjustments and effective therapy even in the presence of detectable porcine inhibitors[1][2].

Financial Impact

The financial impact of using rpFVIII versus BPAs, such as rFVIIa, has been evaluated in several studies. While rpFVIII has a higher per-unit cost, the overall financial impact on hospitals is often neutral. Hospital margins were found to be positive with the use of either rpFVIII or rFVIIa, with average margins of $51,548.89 for rpFVIII and $35,943.80 for rFVIIa. Sensitivity analysis suggests that the use of rpFVIII may have no significant impact on hospital finances for the majority of hospitals[3].

Cost Savings and Efficiency

Using rpFVIII as a first-line agent can lead to potential cost savings compared to BPAs. Studies have shown that the total use of rpFVIII for initial bleed resolution is lower when used upfront, as opposed to being used as rescue therapy. This not only reduces the overall cost but also improves the efficiency of treatment by avoiding the need for multiple doses of BPAs[1][2].

Market Drivers

The market for Hemophilia A treatments, including rpFVIII, is driven by several key factors:

• Rising Prevalence: The increasing number of cases diagnosed each year contributes to the growing demand for treatments.
• Awareness and Access: Improved awareness of the disease and better access to new treatment modalities are significant drivers.
• Prophylactic Treatments: The rise in demand for prophylactic treatments, including recombinant products, is a major market driver[4].

Geographic Distribution

The United States holds a dominant position in the Hemophilia A treatment market, followed by key European countries such as France, Germany, Italy, Spain, and the UK, as well as Japan. These regions are characterized by high awareness of the disease, advanced healthcare infrastructure, and a strong demand for both prophylactic and recombinant treatment options[4].

Challenges and Future Outlook

Despite the advancements in treatment options, Hemophilia A remains a costly and lifelong condition. The high cost of therapies and the need for continuous treatment pose significant challenges. However, the market looks promising due to the ongoing research and development of new treatment modalities, including gene therapies that could potentially offer a cure in the future.

Key Takeaways

• Approval and Clinical Significance: rpFVIII was approved by the FDA in 2014 and offers significant clinical advantages over BPAs.
• Algorithm-Based Dosing: An algorithm-based approach to dosing rpFVIII has been shown to be highly effective and cost-efficient.
• Financial Impact: The use of rpFVIII may have a neutral financial impact on hospitals compared to BPAs.
• Market Drivers: Rising prevalence, awareness, and access to new treatments drive the market.
• Geographic Distribution: The US and key European countries dominate the market.

FAQs

What is the primary advantage of using rpFVIII over BPAs in treating AHA?

The primary advantage of using rpFVIII is the ability to monitor FVIII activity levels and its known hemostatic efficacy, even in the presence of anti-human FVIII inhibitors and after the failure of BPAs[1][2].

How does the dosing algorithm for rpFVIII impact treatment outcomes?

The algorithm-based approach to dosing rpFVIII allows for rapid dose adjustments and effective therapy at lower doses than the FDA-recommended dosing, leading to improved patient outcomes and potential cost savings[1][2].

What is the financial impact of using rpFVIII compared to BPAs?

The financial impact of using rpFVIII is often neutral compared to BPAs, with hospital margins remaining positive. Despite higher per-unit costs, the overall financial impact is similar for the majority of hospitals[3].

What are the key drivers of the Hemophilia A treatment market?

The key drivers include the rising prevalence of Hemophilia A, increased awareness and access to new treatment modalities, and the growing demand for prophylactic and recombinant treatments[4].

Which regions dominate the Hemophilia A treatment market?

The United States and key European countries such as France, Germany, Italy, Spain, and the UK, as well as Japan, dominate the market due to high awareness and advanced healthcare infrastructure[4].

Sources

1. Recombinant porcine FVIII for bleed treatment in acquired hemophilia A. Blood Advances, 2020.
2. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. PMC, 2020.
3. Evaluating the financial impact of utilizing rpFVIII or rFVIIa during a hospital admission for the diagnosis of acquired hemophilia. PubMed, 2022.
4. Hemophilia A Treatment Market Research Report, Size, Share. Polaris Market Research.
5. FDA Approves Baxter's OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for Acquired Hemophilia A. Baxter Investor Relations, 2014.

Last updated: 2024-12-22